Your Global Leader in Stem Cell Market Research
The Regenerative Medicine (RM) Industry is a rapidly growing market with more than 700+ companies worldwide developing products for therapeutic for use in humans. As with any growing industry, the question becomes, how do you define the Regenerative Medicine Industry?
MONTREAL, MAY 7, 2019 – ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that it has entered into a manufacturing and collaboration agreement with Comprehensive Cell Solutions (CCS), a division of New York Blood Center (NYBC) for the clinical grade production of ExCellThera’s lead cell therapy product, ECT-001. [Read more…]
– ElevateBio to leverage its fully integrated, company building bench-to-bedside capabilities exclusively focused on cell and gene therapies
– ElevateBio’s BaseCamp, an R&D, process development and cGMP manufacturing subsidiary, provides cell and gene expertise for all ElevateBio portfolio companies and selected strategic partners
– $150 MM Series A financing co-led by UBS Oncology Impact Fund Managed by MPM Capital and F2 Ventures joined by EcoR1 Capital, Redmile Group, and Samsara BioCapital
CAMBRIDGE, Mass. — ElevateBio, a Cambridge-based biotechnology holding company, today announced operations to create and build a broad portfolio of cell and gene therapy companies through partnerships with leading academic researchers, medical centers and entrepreneurs. [Read more…]
Treatment for autism is an increasingly important pursuit, as the Center for Disease Control and Prevention (CDC) estimates:
With autism spectrum disorder (ASD) affecting between 1-2% of the population, the condition is becoming of increasing importance and a treatment for autism is becoming a highly sought-after medical breakthrough. [Read more…]
GOSSELIES, BELGIUM – March 26, 2019 – MaSTherCell S.A. a subsidiary of Masthercell Global Inc., a cell and gene therapy-dedicated Contract Development and Manufacturing Organization (CDMO) announces that it has signed a lease agreement for a 5,700m2 (61,354ft²) facility located in Belgium. The new facility will become a state-of-the-art manufacturing and production site designed for late-stage and commercially-approved cell and gene therapy products. The commercial facility is expected to be operational in early 2021.
This new site will significantly expand MaSTherCell’s current European manufacturing capacity. MaSTherCell will continue to use its existing site for both industrialization and early to mid-stage clinical programs.
The facility will include industry 4.0 precepts such as software integration, intelligent equipment and integrated processes with the objective to provide the cell and gene therapy community a lean solution for giving its partners a competitive advantage.
“As a leading CDMO, MaSTherCell has a role to play in solving the current lack of commercial manufacturing capacities in Europe and we believe this facility will be a game changer for market access worldwide,” said Dr. Denis Bedoret, CEO of MaSTherCell SA and President of Masthercell Global. “With this new site, we aim to be the first CDMO in Europe to have a dedicated area for large-scale commercial manufacturing.”
“It was natural for us to set up this state-of-the-art plant in the Gosselies Biopark. Not only will we remain close to our current site and centre of excellence, but also because operating in this world-leading biotechnology cluster will enable us to benefit from a first-class environment in terms of skills, people and know-how.
This new production plant will create several hundred jobs and in addition to being able to count on Belgian expertise to train our teams, being in the heart of Europe will undoubtedly be very attractive for our international recruitment,” said Eric Mathieu, Chief of Operations of MaStherCell SA.
Source: MaStherCell SA (PDF)
